

Minutes

Meeting	Pan Mersey Area Prescribing Committee
Venue	Microsoft Teams online meeting
Date and time	Wednesday 21 October 2020, 2.00-3.30pm

Attendance		
AL-JAFFAR, Hannah	Southport and Ormskirk Hospital NHS Trust	Y
ATKINSON, Anna	Lancashire and South Cumbria NHS Foundation Trust	Y
BARKER, Catrin	Alder Hey Children's NHS Foundation Trust	Y
BARNETT, Rob Dr	Liverpool Local Medical Committee	N
BARTON, Carolyn	NHS Knowsley CCG	Y
CAMPBOR, Ivan Dr	Mid Mersey Local Medical Committee	N
CARTWRIGHT, Nicola	NHS St Helens CCG	Y
CHILTON, Neil	North West Boroughs Healthcare NHS Foundation Trust	Y
COLLINS, Daniel	Liverpool Women's Hospital NHS Foundation Trust	N
CROSBY, John Dr	Mersey Care NHS Foundation Trust	N
CULLUMBINE, Ann Dr	Wirral Local Medical Committee	Y
DOYLE, Catherine Dr	NHS Warrington CCG	Y
EVANS, Alison	Wirral University Teaching Hospital NHS Foundation Trust	Y
FITZGERALD, Richard Dr	Liverpool University Hospitals NHS Foundation Trust (Royal)	Y
FORDE, Claire Dr	NHS Halton CCG	Y
FORREST, Danny	Liverpool Heart and Chest Hospital NHS Foundation Trust	N
HALL, Gareth	Warrington CCG; Halton CCG	N
HAWCUTT, Dan Dr	Alder Hey Children's NHS Foundation Trust	Y
HAYES, Nicola	Warrington and Halton Hospitals NHS Foundation Trust	Y
HENSHAW, Anne	Midlands and Lancashire Commissioning Support Unit	Y
HUNTER, Anna Dr	NHS South Sefton CCG, NHS Southport and Formby CCG	Y
IRVINE, Adam	Cheshire and Merseyside Local Pharmaceutical Committee	N

Attendance		
ISLAM, Jasmeen	Cheshire and Wirral Partnership NHS FT	N
JAEGER, Emma	NHS Wirral CCG	Y
JAIN, Adit Dr CHAIR	NHS Knowsley CCG	Y
JALAN, Saket Dr	NHS Wirral CCG	N
JOHNSTON, Jenny	NHS South Sefton CCG, NHS Southport and Formby CCG	Y
JOHNSTONE, Peter	NHS Liverpool CCG	N
KNIGHT, Lisa	Wirral Community NHS Foundation Trust	N
LLOYD, Barry	NHS West Lancashire CCG	Y
LUNN, Jenny	NHS Warrington CCG	Y
McNULTY, Sid Dr	St Helens and Knowsley Teaching Hospitals NHS Trust	Y
PARKER, James	Liverpool University Hospitals NHS Foundation Trust (Royal)	N
PHILLIPS, Kathryn	Bridgewater Community Healthcare NHS Foundation Trust	Y
RAFFERTY, Sarah	Mersey Care NHS Foundation Trust	N
READE, David Dr	NHS St Helens CCG	N
REID, Lucy	NHS Halton CCG	Y
SKIPPER, Paul	Liverpool University Hospitals NHS Foundation Trust (Royal)	N
SZYNALSKI, Jackie	Mersey Care NHS Foundation Trust, Community Services Division	Y
THORNTON, Dave	Liverpool University Hospitals NHS Foundation Trust (Aintree)	Y
VAN MIERT, Matthew Dr	Wirral University Teaching Hospitals NHS Foundation Trust	N
WELSBY, Mike	St Helens and Knowsley Teaching Hospitals NHS Trust	Y
Non-voting		
DINGLE, Helen	Midlands and Lancashire Commissioning Support Unit	N
DONLON, Kieron	Midlands and Lancashire Commissioning Support Unit	Y
MARSDEN, Ashley	North West Medicines Information Centre	Y
MORONEY, Tamsin	Midlands and Lancashire Commissioning Support Unit	N
READER, Graham	Midlands and Lancashire Commissioning Support Unit	Y
WILSON, Paula	Midlands and Lancashire Commissioning Support Unit	Y

1 Welcome and apologies	
	The Chair welcomed members and accepted apologies from the following: Paul Skipper, James Parker, Gareth Hall, Susanne Lynch (Jenny Johnston attending), Adam Irvine and John Williams (Hannah Al-Jaffar attending).
2 Declarations of interest and quoracy	
	A quoracy check confirmed that this meeting was quorate. There were no declarations of interest for items on the agenda.
3 Minutes of the last meeting	
	The Minutes were agreed to be an accurate record of the meeting on 23 September 2020.
4 Matters arising	
4.1	<u>Antimicrobial Guidance</u> As agreed at the last meeting, an additional comment was added, for clarity, to the dental section of the Antimicrobial Guidance. This was emailed to members, who confirmed by email that they were happy with this amendment.
5 New medicines	
5.1	Grey statement summary Grey 'holding' statements have been produced for the APC website: <u>SOLRIAMFETOL tablets (Sunosi®▼)</u> For excessive daytime sleepiness in narcolepsy. To be reviewed when the NICE TA is published (date currently TBC). <u>SOLRIAMFETOL tablets (Sunosi®▼)</u> For excessive daytime sleepiness in obstructive sleep apnoea. To be reviewed when the NICE TA is published (date currently TBC). Both were approved by the APC.
5.2	Naldemedine for opioid-induced constipation – NICE TA651 A summary of the green statement was provided. The NMSG were unclear on the patient cohort NICE TA651 would target but felt that initial uptake would likely be in palliative care. It was confirmed that naldemedine can be taken at any time of the day but should be taken at the same time each day. NICE do not anticipate a significant cost implication from implementing this TA. The APC approved this statement.
6 Shared care	
6.1	Priadel update The Competition and Markets Authority (CMA) is investigating whether Essential Pharma has abused a dominant market position in relation to lithium-based medicines, which it sells under the brand names 'Priadel' and 'Camcolit', by proposing to withdraw the supply

	<p>of Priadel to UK patients. As a consequence, Essential Pharma will pause its plans and will not discontinue Priadel in April 2021 and will continue to supply it, while discussions with the Department of Health and Social care on pricing resume. Therefore, there is no need to put plans in place for switching patients before April 2021. MLCSU will keep the committee up to date with further developments.</p>	
7	Formulary and Guidelines	
7.1	<p>Botulinum toxin type A for axillary hyperhidrosis</p> <p>This is a routine review of the current statement and there are no significant changes. It was included on the consultation email for noting in January. It has been brought to APC now as it supports the botulinum toxin commissioning policy which will go to CCGs for ratification next week and will bring the statement and the policy in line with each other. APC members were asked if they would approve the updated statement and if they would be happy for the current CCG approvals to be carried over.</p> <p>It was agreed that a note will be added to explain that different brands have different potencies and therefore brands are not interchangeable, on a dose basis.</p> <p>The APC approved the statement subject to the above amendment and agreed to carrying over the current CCG approvals.</p>	GR
7.2	<p>Botulinum toxin type A for chronic anal fissures</p> <p>This is a routine review of the current statement and there are no significant changes. It was included on the consultation email for noting in January. It has been brought to APC now as it supports the botulinum toxin commissioning policy which will go to CCGs for ratification next week and will bring the statement and the policy in line with each other. APC members were asked if they would approve the updated statement and if they would be happy for the current CCG approvals to be carried over.</p> <p>It was agreed that a note will be added to explain that different brands have different potencies and therefore brands are not interchangeable, on a dose basis. It was noted that one Trust stated that occasional patients with scarring would not be suitable for topical treatment prior to botulinum toxin, but the majority view was in agreement with the statement as it was.</p> <p>The APC approved the statement subject to the above amendment and agreed to carrying over the current CCG approvals.</p>	GR
7.3	<p>Avoidance of <i>Clostridium difficile</i> infection</p> <p>This is an update of the current guideline at routine review-by date and minor issues were resolved during consultation.</p> <p>APC members were asked if they would be happy to approve the updated guideline and its addition to the static list. CCG members were asked for their agreement to carry over current CCG approvals to this document.</p> <p>The Chair thought this guideline should be circulated by Meds Man teams to raise awareness and for education. DH pointed out that in the PPI section, where it mentions overuse of PPIs, the article it links to is about adult patients; it was agreed that this will be clarified in the document.</p>	GR

	The APC approved the guideline, its addition to the static list, and carrying over current CCG approvals.	
7.4	<p>Silk garments for eczema or atopic dermatitis.</p> <p>This is an update of a current statement which states that silk garments are not suitable for prescribing. Feedback was generally in agreement and any minor points have been addressed. The APC approved this statement, its addition to the static list, and carrying over current CCG approvals.</p>	
8 APC reports		
8.1	<p>NICE TA Adherence Checklist (September 2020) – for noting</p> <p>Pan Mersey APC is compliant up to the end of September 2020. This report will be uploaded to the website.</p>	
8.2	<p>RMOC update</p> <p>The latest RMOC North meeting was held on 29 September. The shared care definition documents are still with NHSE waiting to be signed off; once they have been approved, they will be published, and two draft shared care protocols are ready to be sent out for consultation. AH proposed asking the Shared Care Subgroup to feed back comments on behalf of APC, which was agreed. If timescales allow, they will also be circulated via the APC consultation process for individual comments.</p> <p>There has been ongoing debate over whether RMOC North should split into RMOC NW and RMOC NE in line with the new NHSE regional structure. At this point in time the general consensus is that there is no benefit from a split so it will continue as RMOC North for 12 months, then be reviewed again. A membership review is in progress to ensure there is a balanced representation from across the full geography of RMOC North, which will increase the overall membership number. It has been agreed to also increase the lay membership to ensure the patient voice is heard within the larger membership. The next step is to identify themes for a 'do once' approach by RMOC and APCs are being asked to share their workplans to inform this.</p> <p>Ashley Marsden from the RMOC co-ordinating hub introduced herself and informed the committee that there are two RMOC documents currently out for consultation. AH advised the committee that these documents have been received and passed to the appropriate Pan Mersey subgroups for comment.</p>	AH
9 Online Polling and Capturing APC Decisions		
	<p>KD has been looking at various options to enable online voting. One stumbling block is that software can be at different stages of update from one organisation to the next. His conclusion so far, is that there is not one system consistently available for all Pan Mersey APC members that would provide the required functionality. He listed the options he had tried. KD has escalated the problems he has encountered to the MLCSU Cloud team.</p> <p>It was noted that today's virtual "show of hands" went well but it could be smoother. Members were asked what system they used in other meetings. General comments reported that members felt the online APC meetings worked well and some felt the APC meetings ran better online than some of the other meetings they attended, including</p>	

	<p>national meetings such as the MHRA. There was agreement that silence or lack of objection should not be taken as an indication that members were in agreement and the committee wanted to continue to use the virtual “show of hands” to ensure an active and positive affirmation from members for each agenda item.</p> <p>With reference to a member of the MLCSU team sharing their screen with attendees so that documents were visible to all on the Microsoft Teams call, members indicated they would prefer to look at their own meeting documents and felt that the screen sharing did not add any value. Some members felt it detracted from the meeting experience.</p>	
10 Any other business		
	None.	
11 Next meeting		
	<p>Wednesday 25 November 2020 at 2.00 – 4.00 pm Online meeting via Microsoft Teams</p>	